The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
